DK1135166T3 - Hapten-bærer-konjugat til behandling og forebyggelse af nicotinafhængighed - Google Patents

Hapten-bærer-konjugat til behandling og forebyggelse af nicotinafhængighed

Info

Publication number
DK1135166T3
DK1135166T3 DK99964009T DK99964009T DK1135166T3 DK 1135166 T3 DK1135166 T3 DK 1135166T3 DK 99964009 T DK99964009 T DK 99964009T DK 99964009 T DK99964009 T DK 99964009T DK 1135166 T3 DK1135166 T3 DK 1135166T3
Authority
DK
Denmark
Prior art keywords
nicotine
hapten
conjugates
prevention
treatment
Prior art date
Application number
DK99964009T
Other languages
English (en)
Inventor
Ali Ibrahim Fattom
Robert B Naso
Sofiane Ennifar
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22747358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1135166(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Application granted granted Critical
Publication of DK1135166T3 publication Critical patent/DK1135166T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK99964009T 1998-12-01 1999-12-01 Hapten-bærer-konjugat til behandling og forebyggelse af nicotinafhængighed DK1135166T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/201,800 US6232082B1 (en) 1998-12-01 1998-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction
EP99964009A EP1135166B9 (en) 1998-12-01 1999-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction

Publications (1)

Publication Number Publication Date
DK1135166T3 true DK1135166T3 (da) 2005-02-14

Family

ID=22747358

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99964009T DK1135166T3 (da) 1998-12-01 1999-12-01 Hapten-bærer-konjugat til behandling og forebyggelse af nicotinafhængighed

Country Status (26)

Country Link
US (7) US6232082B1 (da)
EP (3) EP1135166B9 (da)
JP (2) JP4971542B2 (da)
KR (1) KR100656836B1 (da)
CN (2) CN1220521C (da)
AT (1) ATE279211T1 (da)
AU (1) AU763001B2 (da)
BR (1) BR9915852A (da)
CA (1) CA2352765C (da)
DE (1) DE69921178T2 (da)
DK (1) DK1135166T3 (da)
EA (1) EA004956B1 (da)
ES (1) ES2229800T3 (da)
HK (2) HK1042428B (da)
HU (1) HUP0104365A3 (da)
IL (2) IL143474A0 (da)
ME (1) MEP34208A (da)
MX (1) MXPA01005511A (da)
NO (1) NO331998B1 (da)
NZ (1) NZ512103A (da)
PL (1) PL199253B1 (da)
PT (1) PT1135166E (da)
RS (1) RS51273B (da)
TR (1) TR200102411T2 (da)
WO (1) WO2000032239A1 (da)
ZA (1) ZA200104477B (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
AU2002251821A1 (en) * 2001-01-26 2002-08-06 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20030148260A1 (en) * 2001-08-07 2003-08-07 Bernard Levin Method of diagnosing colorectal adenomas and cancer using proton maggnetic resonance spectroscopy
CA2477268A1 (en) * 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
KR101228376B1 (ko) * 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
US20040115244A1 (en) * 2002-12-17 2004-06-17 Holgate Eric Jamison Methods and compositions for nicotine replacement therapy
DK1803443T3 (da) * 2002-12-20 2019-02-25 Niconovum Ab Nikotinholdigt partikelformigt materiale med en krystallinsk cellulose
WO2005040338A2 (en) * 2003-05-21 2005-05-06 The Scripps Research Institute Constrained alkaloid immunogens and antibodies and uses thereof
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20060252107A1 (en) * 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
WO2007064478A2 (en) * 2005-11-28 2007-06-07 Nabi Biopharmaceuticals Method for making nicotine hapten
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US7547712B2 (en) * 2006-02-27 2009-06-16 Nabi Biopharmaceuticals Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
CA2646942C (en) 2006-03-16 2014-07-29 Modoral Brands Inc. Improved snuff composition
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
EP1849780A1 (en) 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CA2917512C (en) 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
EP2065398A1 (en) * 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
JP2011504893A (ja) * 2007-11-29 2011-02-17 サイトス バイオテクノロジー アーゲー ヒト・モノクローナル・ニコチン特異的抗体
US20110086063A1 (en) * 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
MX2010013583A (es) * 2008-06-13 2011-05-19 Nabi Biopharmaceuticals Kit y metodo para dejar de fumar.
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
PL2313390T3 (pl) * 2008-08-08 2013-03-29 Novartis Ag Proces otrzymywania haptenów na bazie nikotyny
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
WO2010067262A1 (en) 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
WO2011014679A1 (en) 2009-07-31 2011-02-03 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
EA023897B1 (ru) * 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
US20120225087A1 (en) * 2009-09-14 2012-09-06 The Scripps Research Institute Nicotine haptens, immunoconjugates and their uses
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
EP2547362B1 (en) 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
US20140039063A1 (en) * 2011-01-04 2014-02-06 National Jewish Health Leukotrienes and asthma exacerbation risk
MX356426B (es) 2011-04-04 2018-05-29 Univ Iowa Res Found Metodos para mejorar inmunogenicidad de vacuna.
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
TWI600905B (zh) * 2012-09-21 2017-10-01 國立臺灣師範大學 聚合半抗原成為免疫原的技術方法
US9303013B2 (en) * 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
CA2949667C (en) * 2014-05-19 2022-05-03 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
CN104402992B (zh) * 2014-11-28 2018-09-18 杭州安旭科技有限公司 一种合成大麻抗原的合成方法及合成大麻抗原的应用
EP3247380A1 (en) * 2015-01-20 2017-11-29 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CN106496309A (zh) * 2016-11-24 2017-03-15 北京开景基因技术有限公司 微球抗原及其制备方法以及抗可替宁抗体的制备方法
MY204084A (en) 2017-06-11 2024-08-06 Molecular Express Inc Methods and compositions for substance use disorder vaccine formulations and uses thereof
WO2019036419A1 (en) 2017-08-15 2019-02-21 Kalnik Matthew W NEW NICOTINE BINDING ANTIBODIES
CN108362891B (zh) * 2017-12-27 2020-09-25 北京勤邦生物技术有限公司 一种泼尼松的磁免疫化学发光检测试剂盒及其应用
US12571547B2 (en) 2018-03-09 2026-03-10 Heds Holdings Llc Hybrid geothermal, air source, water source systems
US11073296B2 (en) 2018-03-09 2021-07-27 Scot Matthew Duncan High efficiency dehumidification system (HEDS)
CN112512549A (zh) * 2018-06-06 2021-03-16 安蒂多特疗法公司 改善循环和治疗心血管疾病的方法
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
CN115583992B (zh) * 2022-11-02 2026-02-17 江南大学 一种氧化还原响应的载体蛋白及其在制备疫苗中的应用
CN116747315A (zh) * 2023-06-20 2023-09-15 中国科学院长春应用化学研究所 高dar值的抗体-免疫调节药物偶联物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3888886A (en) 1972-06-08 1975-06-10 Mobil Oil Corp Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US4053459A (en) 1975-09-24 1977-10-11 Hoffmann-La Roche Inc. Antibody specific to methaqualone and its metabolites
US4235864A (en) 1978-04-10 1980-11-25 Research Corporation Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites
US4376825A (en) 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4666837A (en) 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
SU1123704A1 (ru) 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов
AU5444386A (en) 1985-03-08 1986-09-11 Baylor College Of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and polyclonal)
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4791067A (en) 1987-06-25 1988-12-13 Fisher Scientific Co. Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent
EP0311383B1 (en) 1987-10-09 1993-10-06 Ube Industries, Ltd. Monoclonal antibody to methamphetamine, preparation of the same, assay method and assay kit of methamphetamine
US5268276A (en) 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
EP0363041A1 (en) 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine
GB9001694D0 (en) 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
CH678394A5 (da) 1990-08-22 1991-09-13 Cerny Erich H
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5290784A (en) * 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
US5233042A (en) 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5283066A (en) 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
AU4377793A (en) 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
DE69332637T2 (de) 1993-03-04 2003-10-23 Matsushita Electric Industrial Co., Ltd. Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
US5375414A (en) 1993-10-04 1994-12-27 Ford Motor Company Automotive engine exhaust aftertreatment system including hydrocarbon adsorber with internal engine purge flow control
CA2187336A1 (en) 1994-04-08 1995-10-19 Henry M. Franzen Pharmaceutical formulations for treating japanese cedar pollen allergy
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
ATE254930T1 (de) 1995-03-31 2003-12-15 Xenova Res Ltd Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
US5840307A (en) 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
AU749305B2 (en) * 1997-09-19 2002-06-20 Serex, Inc. Methods to improve immunogenicity of antigens and specificity of antibodies
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Also Published As

Publication number Publication date
HUP0104365A3 (en) 2002-05-28
EP1135166B9 (en) 2005-02-02
JP4971542B2 (ja) 2012-07-11
US6232082B1 (en) 2001-05-15
CN1768861A (zh) 2006-05-10
HK1091415A1 (zh) 2007-01-19
EA200100610A1 (ru) 2002-04-25
NO20012589L (no) 2001-07-20
HK1042428B (en) 2005-07-29
JP2002531421A (ja) 2002-09-24
EA004956B1 (ru) 2004-10-28
WO2000032239A9 (en) 2002-08-22
EP1135166A1 (en) 2001-09-26
NO331998B1 (no) 2012-05-21
HK1043061B (zh) 2006-07-07
TR200102411T2 (tr) 2002-01-21
CN1220521C (zh) 2005-09-28
US20110217320A1 (en) 2011-09-08
US6773891B2 (en) 2004-08-10
ZA200104477B (en) 2002-01-16
RS51273B (sr) 2010-12-31
ES2229800T3 (es) 2005-04-16
CA2352765C (en) 2011-02-15
NO20012589D0 (no) 2001-05-25
EP1135166B1 (en) 2004-10-13
AU2033500A (en) 2000-06-19
MXPA01005511A (es) 2004-08-19
US20020004208A1 (en) 2002-01-10
US6518031B2 (en) 2003-02-11
HK1042428A1 (en) 2002-08-16
EP2324855A1 (en) 2011-05-25
US20050136047A1 (en) 2005-06-23
BR9915852A (pt) 2004-06-29
US7247502B2 (en) 2007-07-24
PL349012A1 (en) 2002-06-17
CN100586481C (zh) 2010-02-03
AU763001B2 (en) 2003-07-10
US7776620B2 (en) 2010-08-17
EP1512414A1 (en) 2005-03-09
US8026109B2 (en) 2011-09-27
DE69921178D1 (de) 2004-11-18
MEP34208A (en) 2011-02-10
IL143474A (en) 2006-06-11
CN1329508A (zh) 2002-01-02
PL199253B1 (pl) 2008-08-29
IL143474A0 (en) 2002-04-21
JP2011079849A (ja) 2011-04-21
PT1135166E (pt) 2005-01-31
HUP0104365A2 (hu) 2002-04-29
KR20010090854A (ko) 2001-10-19
US20110002957A1 (en) 2011-01-06
ATE279211T1 (de) 2004-10-15
NZ512103A (en) 2003-09-26
WO2000032239A1 (en) 2000-06-08
YU39601A (sh) 2003-10-31
KR100656836B1 (ko) 2006-12-12
CA2352765A1 (en) 2000-06-08
US20080026000A1 (en) 2008-01-31
HK1043061A1 (en) 2002-09-06
DE69921178T2 (de) 2005-11-17
US20030165950A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
PT1135166E (pt) Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina
DK1024834T3 (da) Hapten bærer konjugater til anvendelse ved stofmisbrugsterapi og fremgangsmåder til fremstilling af samme
UA88599C2 (ru) Коньюгат производное калихеамицина-антитело, способ его получения и способы лечения
DE60234782D1 (de) Behandlungsverfahren mit liganden-immunogenkonjugaten
NO20012409L (no) Anvendelse av paclitaxel stabilisert med albumin for fremstilling av et legemiddel for behandling av faste tumorer, oglegemiddel erholdt derved
DK1202736T3 (da) Nikotin i terapeutisk angiogenese og vasculogenese
DK1329226T3 (da) Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
NO20015073L (no) Vaksiner
ATE109008T1 (de) T-zellen-epitope als träger für einen konjugierten impfstoff.
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
CY1111814T1 (el) Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων
CY1110140T1 (el) Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
ATE452654T1 (de) Polyalkylenoxid-konjugate von thiolhaltigen arzneistoffen
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung